NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD — Investor Relations & Filings

NeuroScientific Biopharmaceuticals Ltd is a clinical-stage drug development company focused on creating peptide-based therapeutics for neurodegenerative disorders and ocular diseases. The company’s primary research centers on its lead drug candidate, EmtinB, a synthetic peptide modeled after the active domain of the human protein metallothionein-II. EmtinB is designed to promote neuroprotection and neuroregeneration by activating specific cell signaling pathways that prevent cell death and stimulate the repair of damaged neurons. The company targets high-unmet-need conditions, including Alzheimer’s disease, Multiple Sclerosis, and various forms of optic nerve damage such as glaucoma and optic neuritis. By leveraging biological mechanisms that mimic natural physiological responses to injury, NeuroScientific Biopharmaceuticals aims to provide disease-modifying treatments that improve clinical outcomes for patients with central nervous system and ophthalmic pathologies.